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Case presentation
A 57-year-old female, a retired beautician, was referred to Parkiand
Memorial Hospital for evaluation and treatment of persistent hyperka-
lemia. She had been in excellent health until approximately 12 years
earlier, when she underwent a laminectomy for a herniated nucleus
pulposus. The surgery was uneventful and her convalescence was
uncomplicated except for the loss of 70 lbs (178 to 108 Ibs) during the 7-
month period that she was confined to a body cast. When the cast was
removed, she experienced a syncopal episode. A complete evaluation
at another hospital suggested that the syncope was the result of
orthostatic hypotension. Pertinent aspects of her workup included a
normal electromyogram, electrocardiogram, serum protein electropho-
resis, and upper gastrointestinal series. Laboratory findings revealed:
hematocrit, 42%; total protein, 8.3 g/dl; albumin, 5.3 g/dl; BUN, 9 mg/
dl; T3 resin uptake, 25%; T4, 4.8 sg/dl; 24-hour urine 17-OH steroids, 12
mg/24 hr (normal <10 mg/24 hr); and 17 ketosteroids, 7 mg/24 hr
(normal 5—15 mg/24 hr). Serum electrolytes were reported as normal.
She was given 9-a-fiuorocortisol, 0.1 mg/day.
The patient continued to complain of dizziness and had several
additional hospital admissions over the ensuing 3 years. Her standing
blood pressure was 60/30 mm Hg. Neurologic workups continued to be
unrevealing. Serum electrolytes remained normal: sodium, 132 mEq/
liter; potassium, 4.5 mEq/liter; carbon dioxide, 24 mEqlliter; and BUN,
18 mg/dl. Treatment with elastic stockings, ephedrine, and an antigrav-
ity suit were prescribed. The dose of 9-n-fluorocortisol gradually was
increased to 0.6 mg/day.
Hyperkalemia (serum potassium, 5.7 mEq/liter) was documented for
the first time 8 years ago. Six years ago the 24-hour urinary aldosterone
level was "non-detectable" while she was ingesting a low-sodium diet;
serum aldosterone was 2 ng/dl 4 hours after assuming the upright
posture and receiving a diuretic, and plasma cortisol after ACTH
injection was 2 sg/dl at 4 PM. She also had a subnormal response of
plasma cortisol to an 8-hour ACTH infusion but the metyrapone test
was normal; il-DOC increased to 3 sg/dl and serum cortisol fell
slightly. She was advised at that time to increase 9-n-fluorocortisol to
1.0 mg/day.
For the past 5 years she has not only been hypotensive, but also
severely hyperkalemic, the serum potassium concentrations frequently
being greater than 7.0 mEq/liter with a peak value of 9.9 mEq/liter.
When the serum potassium exceeded 9.0 mEq/liter, generalized weak-
ness and occasional frank paralysis occurred. Serum potassium values
have remained markedly elevated despite therapy with sodium polysty-
rene sulfonate (Kayexalate). The course has been further complicated
by occasional periods of hypokalemia, occurring when the cation
exchange resin was increased in conjunction with a decreased intake of
potassium. Creatinine clearance 5 years ago was 55 mI/mm.
A repeated endocrine evaluation 4 years ago revealed: supine plasma
aldosterone, 3 ng/dl (normal 3—10 ng/dl); upright plasma aldosterone, 2
ng/dl (normal 5—30 ng/dl); 24-hr urinary aldosterone, 3 g/24 hr (normal
4—20 g/24 hr); supine plasma renin, 3.5 ng of angiotensin generated/mI!
hr (normal 0.5—1.6 ng/ml/hr); 2-hour upright plasma renin, 18.4 ng of
angiotensin generated/ml/hr (normal 1.9—3.6 ng/mllhr); 24-hour urinary
17-ketosteroids, 4.8 mg/24 hr (normal 5—15 mg/24 hr); 24-hour urinary
17-OH-steroids, 10.6 mg/24 hr (normal 4—8 mg/24 hr); and plasma
cortisol, 30.7 g/dl at 8 AM and 20.4 jsg/dl at noon (normal 7—27 jsg/dl at
9 AM). Although a value for serum potassium was not recorded
simultaneously, the most likely diagnosis appeared to be isolated
hyperreninemic hypoaldosteronism.
One year ago she again experienced periods of weakness, She also
had reductions in serum sodium to 106 mEq/liter and elevations in
serum potassium to 7.5 mEq/liter despite high doses of sodium polysty-
rene sulfonate and 9-a-fiuorocortisol. However, her symptoms persist-
ed and the metabolic abnormalities remained difficult to control. For
these reasons she was admitted to the Clinical Research Center.
Physical examination revealed a pleasant white female who appeared
her stated age. The blood pressure was 80/60 mm Hg supine. In the
sitting position, the systolic blood pressure was 60 mm Hg, but the
diastolic pressure was unobtainable. Respective pulse rates were 60 and
98/mm. The respiratory rate was 18/mm. She was afebrile. The remain-
der of the physical examination was within normal limits.
The laboratory findings were: hematocrit, 38.1%; MCV, 102.2
sodium, 123 mEq/liter; potassium, 6.3 mEq/liter; chloride, 104 mEq/
liter; carbon dioxide content, 15 mM/liter; calcium, 9.5 mg/dl; phospho-
rus, 3.8 mg/dl; BUN, 33 mg/dl; and creatinine, 1.7 mg/dl. The arterial
blood pH was 7.25. Urinalysis disclosed: pH, 6.5; specific gravity,
1.025; and normal sediment. Serum lipids were normal. Serum B12 was
less than 100 pg/mI (normal 210—920 pg/mI), and folic acid was 3.2 ng!ml
(normal 2—14 ng/ml). Electrocardiogram, chest x-ray, and abdominal
computerized tomographic scan were normal.
Renal biopsy revealed scattered areas of complete scarring. Other
areas appeared completely normal. Specifically the distal tubules and
the adjacent interstitium were normal. Each glomerulus, however,
displayed a markedly hyperplastic juxtaglomerular apparatus. Electron
microscopy and immunofluorescence studies failed to demonstrate any
deposits. The biopsy material contained adequate samples both of
cortical and medullary sections.
Because of evident salt depletion, the patient was given a diet
containing 410 mEq of sodium (9.4 g) and 10 mEq of potassium for the
first 2 days. A metabolic diet was then given that contained 260 mEq of
sodium (6 g), 10 mEq of potassium, and 3000 ml fluid per day.
Successive 3-day collections of stool were analyzed; serum and urine
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were analyzed daily. Pertinent metabolic balance data are summarized
in Figures 1 and 2. Sodium balance was achieved on the third hospital
day.
Renin values were 28.2 ng Al/mi/hr supine, and 43.7 ng Al/mi/hr
upright; both values significantly exceed the normal limits. Plasma
epinephrine (determined by C. R. Lake at USUHS, Bethesda, Mary-
land) with the patient in the supine position was 6 pg/mI and 10 pg/mI in
the upright position; both values are within the normal range [1]. Plasma
norepinephrine was 429 pg/mI (normal 200 9 pg/mI) supine, and 1090
pg/mi (normal 409 29 pg/ml) in the upright position [1]. Values for
adrenocorticoids are summarized in Table 1 and Figures 3 and 4; the
concentration of aldosterone and its precursor, 18-OHB, were low
when interpreted in the light of coexisting hyperkalemia. Furthermore,
subnormal increases in these values occurred in response to posture
and ACTH infusion, as well as to rates of angiotensin II infusion
sufficient to increase blood pressure from 98/68 to 116/82 mm Hg.
Baseline glucocorticoid values were normal to high and increased in
response to ACTH infusions (see Table 1). These results were interpret-
ed to indicate that the patient had selective unresponsiveness of the
zona glomerulosa and a normally responsive zona fasciculata.
Discussion
DR. JUHA P. KOKKO (Chief, Section of Nephrology, Univer-
sity of Texas Health Science Center, and Professor of Medi-
cine, Southwestern Medical School, Dallas, Texas): Chronical-
ly elevated serum potassium concentration is rare in patients
whose glonierular filtration rate exceeds 15 mllmin [2]. When
hyperkalemia occurs in association with metabolic acidosis and
renal salt wastage, either selective hypoaldosteronism or failure
of target organs to respond normally to aldosterone should be
considered. Both selective aldosterone deficiency and a failure
to respond normally to aldosterone may be the result of inborn
biosynthetic errors or acquired defects. Inborn errors in infancy
Plasm a
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(mg/dI)0.0
have received the most attention because of their dramatic
presentation and more common recognition; however, acquired
aldosterone defects in adult patients are being increasingly
recognized. The patient under discussion today is unique in that
she has a combination of acquired selective hypoaldosteronism
and a failure of kaliuresis in response to exogenously adminis-
tered mineralocorticoids, despite the fact that mineralocorti-
coids given intramuscularly resulted in a typical antinatriuresis
and increased hydrogen ion secretion.
Hypoaldosteronism can be the result of a decreased stimulus
to the adrenal gland to secrete aldosterone or of an intrinsic
adrenal defect in aldosterone secretion. Primary hyporeninemia
is thought to be a frequent cause of secondary hypoaldosteron-
ism. Diabetes mellitus and chronic renal insufficiency are most
commonly clinically associated with the syndrome of hyporen-
inemic hypoaldosteronism [2—9]. However, it is not at all clear
whether a decreased renin is the cause of the decreased
aldosterone secretory rate in all these patients.
A substantial fraction of patients with primary hyporeninemia
have an abnormal release of aldosterone in response to intrave-
nous angiotensin II infusion [2]; therefore DeFronzo has sug-
gested that, in addition to hyporeninemia, a primary defect
might exist in the adrenal gland. It should be noted, however,
that the patient we are discussing today did not have diabetes
mellitus and that her renal function was only modestly compro-
mised. Furthermore, her renin values, far from being low, were
quite high. Thus she does not fulfill the diagnostic criteria for
the hyporeninemic hypoaldosterone syndrome.
The high renin values are consistent with the clinical findings
of salt depletion due to renal salt wastage (Fig. 2). The plasma
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Fig. 1. Effect of DOCA (10 mg IM bid) on
plasma sodium, potassium, total C02, urea
nitrogen, creatinine, and creatinine clearance.
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norepinephrine values are also consistent with salt depletion.
Previous physicians caring for this patient entertained the
diagnosis of idiopathic orthostatic hypotension without diffuse
neurologic signs and considered the possibility of the Shy-
Drager syndrome. In neurogenic orthostatic hypotension, however,
the recumbent plasma norepinephrine values are low and do not
rise with upright posture, whereas in the Shy-Drager syndrome,
the supine plasma norepinephrine value is normal and does not
rise with upright posture [101. The norepinephrine levels did not
rise in any of the patients with neurogenic orthostatic hypoten-
sion [10]. Thus this patient's norepinephrine values, which were
high in recumbency and rose markedly with standing, are not
consistent with a neurogenic origin to her orthostatic hypoten-
sion, but rather are most consistent with volume depletion. In
further support of this conclusion are the earlier observations
that she had little or no benefit from ephedrine administration.
The coexistence of hypoaldosteronism and high renin values
raises the possibility that hypoaldosteronism could result from a
primary adrenal insensitivity to angiotensin II, due either to a
Fig. 2. Effect of DOCA (10 mg TM bid) on
sodium balance, potassium, urine pH, urine
ammonia, urine titratable acid, and urinary
net acid excretion.
receptor abnormality or to the destruction of the zona glomeru-
losa. In this patient, we evaluated the aldosterone response to
upright posture, to ACTH infusion, and to angiotensin II (see
Table 1). Interpreted in the light of coexistent hyperkalemia, the
baseline results demonstrate low concentrations of zona gb-
merulosa steroids (that is, 18-OHB and aldosterone) and elevat-
ed concentrations of zona fasciculata steroids (that is, cortisol
and corticosterone); DOC and 18-OH DOC can be synthesized
in both zones. Furthermore, the results demonstrate a blunted
response of the zona glomerubosa steroids to all three of the
stimulatory maneuvers employed (see Figs. 3 and 4) [11, 121.
Because the patient had been asymptomatic and had had a
normal electrolyte profile until approximately 10 years ago, the
present results suggest that she has acquired hypoaldosteron-
ism secondary to dysfunction or destruction of the zona
glomerulosa.
Among the more common causes of acquired primary hypoal-
dosteronism due to a primary defect in the zona gbomerulosa are
heparin therapy [13, 141, autoimmune disorders [15—191, and
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Table 1. Plasma steroid concentrations as influenced by posture, ACTH, and All infusions"
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Procedure Time
Aldosterone
ngldl
Cortisol
gidI
DOC
ngldl
Corticosterone
ngldl
18-OHB
ng/dI
10-OH DOC
ngldl
Normal Values 7.3 2.7 9.9 2.9 7.4 2.8 292 127 22.9 8.2 6.0 3.6
Range (4—13) (4—16) (2—13) (38—546) (7—39) (1—13)
Supine 6AM 6.8 22.2 41.6 1517 37.7 13.2
Upright 10 AM 8.0 24.8 63.7 2277 39.4 16.4
ACTH infusion
Control 10 AM 4.6 18.6 15.8 930 20.0 4.5
60' sample 11 AM 6.9 21.6 44.4 2088 33.4 10.5
All Infusion (14 ng/kg/min)
Baseline 3:20 PM 3.6 16.7 17.2 490 16.8 4.5
90' sample 4:50 PM 4.7 12.8 14.1 814 14.0 3.0
"Values were determined by Dr. Morris Schambelan, San Francisco General Hospital. Normal values reflect values determined in his
laboratory [91.
hypotension in the critically ill patient [201. The patient we are
considering here had not received heparin, and she had not
been critically ill with hypotension before she developed the
metabolic abnormality. She does have a variety of allergies, but
we have not been able to perform tests for autoimmune diseases
involving various endocrine organs. Of special interest in this
patient would be serum levels of antibodies against the adrenal
gland and other endocrine organs. It is possible that she will
develop multiple endocrine deficiencies in the future; at pr-
sent, however, her thyroid and parathyroid hormone levels are
normal. It is of interest that her serum B12 levels were low, and
it is tempting to speculate that this finding also might reflect an
underlying autoimmune disorder. Nevertheless, the cause of
her zona glomerulosa malfunction remains unknown.
Once the diagnosis of primary acquired hypoaldosteronism
was made, it was reasonable to expect a metabolic response to
exogenously administered mineralocorticoid. We therefore
treated her with intramuscular desoxycorticosterone acetate
(DOCA) and elected a high-dose regimen (10 mg intramuscular-
ly twice daily) because of her previous apparent unresponsive-
ness to oral 9-a-fluorocortisol. The DOCA was initiated on the
eighth hospital day. The metabolic responses to DOCA are
outlined in Figures 1 and 2. Of interest was the immediate
antiriatriuretic response, positive sodium balance, and an asso-
ciated weight gain. The blood pressure returned to 115/70 mm
Hg with this therapy; this response constituted presumptive
evidence that her hypotension was the result of previous
volume depletion due to renal salt wastage. Also, the urine pH,
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which had been stable at 6.25 to 6.50, immediately began to
drop, reaching a level less than 5.50. In conformity, the
excretion of ammonium and titratable and net acid increased,
and the plasma bicarbonate concentration rose to 23 mEq/liter.
However, neither the stool nor urinary potassium rose during
the subsequent 4 days of metabolic studies, nor did urinary
potassium excretion increase during a month-long period of
DOCA therapy. The urinary potassium concentration has re-
mained consistently less than 7 mEq/liter, and the 24-hour
urinary potassium excretion has been less than 14 mEq. Thus,
the patient appears to have a selective end-organ unresponsive-
ness to the kaliuretic effects of mineralocorticoids while main-
taining a normal response of sodium reabsorption and hydrogen
ion secretion.
Failure of kaliuresis in response to aldosterone can be the
consequence of a specific defect in hormonal response or can be
due to a nonspecific, intrinsic epithelial defect of potassium
secretion. To differentiate these possibilities, one liter of 4%
sodium sulfate containing 44 mEq/liter sodium bicarbonate was
infused. In response to this infusion, the patient had a subnor-
mal kaliuretic response; the highest concentration of urinary
potassium following the infusion was 10 mEq/liter, and the
greatest rise in fractional excretion of potassium was to 13%
from a control of less than 1%. This response, distinctly
subnormal when compared to control subjects similarly exam-
ined [211, implies that this patient has a collecting duct system
that is relatively impermeable to potassium.
The presence of primary hypoaldosteronism in conjunction
with an isolated defect in the kaliuretic response to exogenous
mineralocorticoids represents a unique set of findings. Howev-
er, some clinical syndromes do require high doses of mineralo-
corticoids to correct the metabolic abnormalities. Characteristi-
cally, correction of hyperkalemia in diabetic patients with
hyporeninemic hypoaldosteronism [2] and in some patients with
hyperkalemic varieties of renal tubular acidosis [221 requires
high doses of mineralocorticoids. Other circumstances also
have been recognized in which normal or elevated values of
renin and aldosterone are found but in which the distal tubule
fails to respond to aldosterone. Such "pseudohypoaldosteron-
ism" is well described in infants [23] and is being recognized
with increasing frequency as an acquired defect in adults.
Examples of the latter include renal amyloidosis [24], methicil-
lin interstitial nephritis [25], sickle cell disease [2, 26], and other
disease processes affecting primarily the distal tubule [27]. This
patient, however, had no evidence on renal biopsy of morpho-
logic abnormalities in the peritubular area of the cortex or
medulla. Thus, she does not appear to have any previously
described entity, and the reason for her failure to increase
potassium excretion at a time when DOCA stimulated both
sodium reabsorption and hydrogen ion secretion remains
conjectural.
In an effort to shed further light on this patient's problem, I
now would like to review our current understanding of how
aldosterone affects sodium, potassium, and hydrogen transport
at cellular and subcellular levels.
Sodium transport
One of the cardinal features of all forms of hypoaldosteron-
ism is negative sodium balance, principally due to increased
renal wastage of sodium. In theory, aldosterone's effect on
sodium reabsorption could occur in any nephron segment. In-
vitro microperfusion studies have demonstrated, however, that
the cortical collecting tubule, not the distal convoluted or
medullary collecting tubule, is the principal site at which
chronic mineralocorticoid exposure leads to an increase in net
sodium reabsorption and an increase in lumen-negative poten-
tial [28—34]. Cortical collecting tubules harvested from adrenal-
ectomized rabbits and perfused in the absence of mineralocorti-
coids have a transepithelial potential close to zero and exhibit
negligible levels of sodium reabsorption [28—34]. Thus, there
exists a consensus that chronic mineralocorticoid exposure
stimulates electrogenic sodium absorption across the cortical
collecting tubule.
Figure 5 summarizes the salient features of the cellular and
subcellular mechanisms by which aldosterone is now thought to
stimulate sodium transport across the cortical collecting tubule.
In this model sodium moves down a favorable electrochemical
gradient from lumen to cell via conductive pathways ("pores");
this mechanism was demonstrated recently by the direct micro-
electrode studies of Koeppen, Biagi, and Giebisch [35]. These
pathways probably are not completely free diffusion channels,
but rather are areas where sodium has some interaction with
constituents of the membrane. The permeability of these path-
ways to sodium is inhibited by amiloride [35]. Regardless of the
precise nature of these pathways, sodium diffuses across them
from higher (lumen) to lower (intracellular space) energy levels.
Intracellular sodium in turn is a sensitive substrate for the
sodium-potassium ATPase pump, and the increased availability
of sodium results in increased ATPase activity and increased
transport of sodium across the basolateral membrane.
Aldosterone could increase transepithelial sodium transport
by one of two means, as schematized in Figure 5: an increase in
apical membrane conductance to sodium or an increase in
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Fig. 4. Response of 18-OHB and aldosterone to angiotensin II infusion.
Patient values are depicted in solid triangles; normal control values,
depicted in open circles, are from Kater and Biglieri [121.
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Fig. 5. Model for secondary enhancement of Na-K ATPase by aldos-
terone, A. R is the cytoplasmic mineralocorticoid receptor. In this
model, an increase in intracellular Na activity leads to a secondary
activation of ATPase, which can be blocked by amiloride [461.
Na
sodium-potassium ATPase activity. These two processes could
be either independent or mutually dependent. It also is conceiv-
able that one of these processes is rate limiting.
Figure 6 is a highly schematized model that is consistent with
much of the available physiologic data regarding aldosterone's
influence on transepithelial transport across the cortical collect-
ing tubule. In this model, the rate-limiting step has been placed
at the apical membrane. Whereas the evidence for this hypothe-
sis comes largely from studies of frog skin and toad urinary
bladder [36—42], the conceptual extension to the mammalian
collecting duct is not unreasonable. The sodium channels are
depicted in Fig. 6 as being either open (conductive) or closed
(nonconductive). As shown on the right side of the figure,
aldosterone can be viewed as opening up existing but previous-
ly closed channels. The mechanism by which aldosterone might
accomplish this task is not known, but exciting preliminary
information is evolving. For example, the sodium channels
appear to have stereospecificity. Evidence also suggests that
the proteins that make up these channels have carboxyl resi-
dues [42]. Amiloride is thought somehow to react with these
carboxyl groups and close effectively the channel for sodium
permeation [42]. It thus is tempting to speculate that sodium
conductance through these channels is facilitated by the nega-
tive electrostatic forces of the carboxyl groups. How does
aldosterone affect the opening and closing of these channels?
The answer to this question is not known for certain, but
preliminary data from Wiesmann and colleagues suggest that
methylation of either the structural phospholipid or permease
proteins is involved [43]. This possibility isdepicted in the
bottom panels of Figure 6. Wiesmann et a! added aldosterone to
apical membrane vesicles from cultured A6 cells in the presence
of methylation inhibitors, and could not demonstrate aldoster-
one-stimulated sodium transport. The authors therefore sug-
gested that aldosterone somehow stimulates methylation,
which in turn increases sodium conductance in the channel.
Perhaps the methylation involves the carboxyl groups, as
suggested in Fig. 6, but admittedly there are many other ways
by which methylation (or other molecular mechanisms) could
culminate in an increased number of conductive sodium chan-
nels [41]. There is no convincing evidence that, once the sodium
gains access to the intracellular compartment, aldosterone in
any way regulates its intracellular diffusion (or transport) from
the apical to the basolateral membrane; sodium is thought to
diffuse freely in the cytoplasmic milieu.
Increasing the activity of the sodium-potassium ATPase
pump on the basolateral membrane increases the efilux of
sodium from the cell and, in the absence of other epithelial
effects, increases transepithelial movement of sodium. Indeed,
many studies have shown that treating animals with mineralo-
corticoids increases the sodium-potassium ATPase activity of
the cortical collecting tubule [44—50]. There are three principal
substrates for the sodium-potassium ATPase: ATP, potassium,
and sodium, In theory, aldosterone could affect any one of
these substrates either directly or indirectly. Whereas a large
body of evidence supports the view that aldosterone can
increase mitochrondrial metabolism and thereby increase ATP
availability to the sodium-potassium ATPase pump, mitochon-
drial performance is not thought to be rate limiting; therefore
aldosterone probably does not regulate sodium-potassium
ATPase activity primarily by influencing cellular metabolism
[51]. Also, the possibility that aldosterone affects sodium-
potassium ATPase activity by altering extracellular potassium
concentration at the basolateral membrane is unlikely. But, as
discussed previously, aldosterone does cause increased entry of
sodium from the lumen via the conductive pathways. Aldoster-
one thus could increase pump activity by increasing the avail-
ability of one of the sodium-potassium ATPase substrates,
namely sodium. The studies by Petty, Kokko, and Marver have
addressed this issue directly [461. Cortical collecting tubules of
adrenalectomized rabbits were shown to increase the sodium-
potassium ATPase activity in response to the acute administra-
tion of aldosterone only if sodium was permitted to enter the
collecting tubule cell. If the rabbits were pretreated with the
sodium channel blocker amiloride, the expected rise in sodium-
potassium ATPase did not occur. These studies are consistent
with the hypothesis that aldosterone increases sodium-potassium
Fig. 6. Cellular model of the cortical collecting tubule. Some sodium
channels are open and some are closed during control conditions (left
panel) but all open in response to aldosterone (right panel).
Blood
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ATPase activity as a consequence of increased apical entry of
sodium. In addition, aldosterone might directly affect the syn-
thesis of subunits of ATPase [52], but these effects might not be
rate limiting.
Potassium transport
Hyperkalemia is a common finding in untreated patients with
severe hypoaldosteronism. Indeed, persistent hyperkalemia in
the absence of chronic renal failure, acid-base disturbances,
and specific drugs affecting potassium secretion should prompt
the physician to consider the diagnosis of hypoaldosteronism.
Whether mineralocorticoids directly affect potassium secre-
tion has been difficult to establish. After an exhaustive review
of the literature, Rabinowitz concluded that most reported
clearance studies failed to demonstrate an acute effect of
aldosterone on potassium secretion [53]. In keeping with this
conclusion, most patients given mineralocorticoids do not in-
crease potassium excretion unless they have an adequate intake
of sodium [54, 55].
Urinary potassium excretion is primarily regulated by trans-
port processes occurring across distal tubular segments. The
transport of potassium across these segments occurs by active
as well as passive mechanisms and is influenced by a number of
factors, some of which have a direct epithelial effect on the
regulation of potassium excretion, whereas others affect potas-
sium excretion secondarily. Factors affecting distal potassium
excretion can be divided into two subgroups, tubular (for
example, rate of luminal flow, rate of transepithelial sodium
reabsorption, and transepithelial potential difference) and sys-
temic (for example, dietary potassium intake, acid-base status,
hormonal levels). In view of these complexly interacting fac-
tors, experiments designed to determine whether mineralocorti-
coids have a direct epithelial effect on potassium transport must
be conducted under well-defined circumstances in which all the
potential influences on potassium transport are controlled.
Studies using the isolated tubule technique are interesting in
this respect. Recent in-vitro studies have demonstrated that
collecting tubules harvested from adrenalectomized rabbits do
not increase potassium secretion over the first 120 minutes of
exposure to aldosterone in vitro despite a clear increase in net
sodium reabsorption [561. These studies support the view that
mineralocorticoids do not directly stimulate potassium secre-
tion acutely in the cortical collecting tubule. However, tubules
dissected from rabbits given DOCA chronically have a higher
rate of potassium secretion than do tubules dissected from
rabbits that have not received DOCA [57—59]. There seems to
be a good correlation between plasma levels of mineralocorti-
coids and the potassium secretory rate of the cortical collecting
tubule 158]. The view thus is developing that the cortical
collecting tubule responds to aldosterone in a biphasic manner:
acutely, there seems to be no direct effect of aldosterone on
potassium secretion, but chronically potassium secretion is
stimulated [56].
The mechanism of transcellular potassium transport in the
cortical collecting tubule and the possible effect of mineralocor-
ticoids on this mechanism have been explored recently with
microelectrode measurements. These measurements have dis-
closed that the mean intracellular potential difference is -84 mV
with respect to the blood side [35] and that this tubular segment
is composed of two subpopulations of cells with the predomi-
nant cell type having a more negative potential difference across
the basolateral membrane [60]. With chronic mineralocorticoid
treatment, the mean potential difference became more negative
in randomly punctured cells (—105 mY) [35]. Thus, chronic
mineralocorticoid treatment can increase the influx of potassi-
um across the basolateral membrane by two mechanisms: (1) an
increase in sodium-potassium ATPase activity as previously
discussed, and (2) an increase in the passive entry of potassium
across the basolateral membrane down a presumably favorable
electrochemical gradient [35]. When potassium gains entrance
to the cell, it can leave either across the apical or basolateral
membrane. Microelectrode studies have demonstrated separate
channels for sodium and potassium conductance at the apical
membrane with the conductance for potassium being much
greater [35, 61]. There also exists a conductive pathway for
potassium at the basolateral membrane [35, 60, 61]. But be-
cause the lumen of the cortical collecting duct is negative with
respect to the blood side under most circumstances, and
because the lumen becomes more negative with chronic mm-
eralocorticoid therapy, there is a preferential driving force for
potassium to leave the cell across the apical rather than the
basolateral membrane. Furthermore, the studies by Koeppen et
al have suggested that chronic DOCA administration preferen-
tially increases the potassium conductance of the apical mem-
brane to some extent [35]. These studies indicate that chronic
exposure to mineralocorticoids can increase potassium secre-
tion across the cortical collecting tubule cells by mechanisms
other than simply increasing sodium-potassium ATPase
activity.
In addition to increasing the transcellular secretory move-
ment of potassium, mineralocorticoids also facilitate the para-
cellular influx of potassium from blood to lumen. The evidence
for the existence of this pathway comes from the observations
that the cortical collecting tubule is finitely permeable to
potassium, and that potassium transport depends on the trans-
epithelial potential difference in a linear fashion [59, 62]. It is
not clear what fraction of the kaliuresis induced by aldosterone
in vivo stems from transcellular and what fraction from paracel-
lular secretion.
Hydrogen transport
Metabolic acidosis is a common manifestation of hypoaldos-
teronism. This finding is in keeping with the inference drawn
from clearance studies that mineralocorticoids play a role in
regulating hydrogen ion excretion [63]. Recent in-vitro micro-
perfusion studies have localized the nephron site of bicarbonate
reabsorption and/or secretion, and have explored the role of
mineralocorticoids in these transport processes [64—68].
The cortical collecting duct is unique among nephron seg-
ments because it can secrete as well as reabsorb bicarbonate.
McKinney and Burg, the first to demonstrate this phenomenon,
showed that tubules harvested from acidotic rabbits reabsorbed
bicarbonate, whereas tubules harvested from alkalotic rabbits
secreted bicarbonate [64—66]. Similar results were later ob-
tained by Lombard, Kokko, and Jacobson [67]. Koeppen and
Helman further demonstrated that the more negative the lumen
potential difference, the more aci&c the lumen pH [68]. This
finding is not surprising in view of the finite permeability of the
tubule to hydrogen ion (1.3 x l0 cm/see) [691; morever, the
finding at least partially explains the reduction in luminal pH
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Fig. 7. Model of hydrogen secretion by the medullary collecting tubule.
Lumen-positive potential is represented by plus signs.
produced by chronic DOCA administration [681. One might
postulate from these observations that the cortical collecting
tubule has an important role in the overall regulation of acid-
base balance; this may not be the case, however, because the
capacity of the cortical collecting tubule to either reabsorb or
secrete bicarbonate is limited, being only a fraction of the
capacity of the outer medullary collecting duct to reabsorb
bicarbonate [671.
In-vitro microperfusion studies have shown that the outer
medullary collecting duct always reabsorbs bicarbonate wheth-
er the tubules were harvested from acidotic or alkalotic rabbits
[67]. This finding stands in marked contrast to the previously
mentioned findings in the cortical collecting tubules, where the
direction of bicarbonate transport critically depends on the
acid-base status of the rabbit.
Figure 7 depicts our current concepts about the transcellular
transport of hydrogen ion across the outer medullary collecting
duct. According to this view, the transepithelial reabsorption of
bicarbonate (or secretion of hydrogen) does not depend on
sodium transport. Evidence for this belief stems from the
finding that bicarbonate reabsorption is unaffected either by the
presence of amiloride in the lumen or by the total replacement
of luminal sodium with tetramethylammonium [70]. The sodi-
um-independent, hydrogen ion secretory mechanism is associ-
ated with a lumen-positive transepithelial potential difference
[67, 70—72] (Fig. 7). To examine the mechanism whereby base
exits the cell across the basolateral membrane, we bathed
tubules in commonly employed, chloride-containing solutions
and in solutions in which chloride had been substituted with
gluconate [71]. Chloride removal reduced transepithelial reab-
sorption of bicarbonate to zero; this finding is most consistent
with the presence of a chloride-bicarbonate (or hydroxyl)
exchange mechanism at the basolateral membrane. Figure 7
depicts chloride as being secreted along both transcellular and
paracellular routes. Although our studies indicate that hydrogen
and chloride are secreted at the same rate [71], it is not possible
currently to determine precisely what fraction of chloride
transport occurs through the cell, because the apical and
basolateral conductances to chloride across the outer medullary
collecting duct cells have not yet been determined.
Recent preliminary studies by Stone et al, using luminal
fraction-enriched vesicles from bovine renal medulla, have
provided evidence for the existence of a proton-translocating
ATPase [72]. If further studies unequivocally establish the
presence of hydrogen-ATPase on the apical membrane, the
hydrogen secretory model depicted in Figure 7 will gain further
support.
Do mineralocorticoids have a role in stimulating hydrogen
secretion? Stone et al have shown that both acute exposure of
tubules to aldosterone and chronic administration of mineralo-
corticoids to rabbits significantly increase bicarbonate reab-
sorption [70]. This mineralocorticoid-stimulated increase in
hydrogen ion secretion occurred in the absence of luminal
sodium [701. Glucocorticoids did not influence bicarbonate
reabsorption across the outer medullary collecting duct. In view
of these findings and because of the demonstration that aldos-
terone does not affect sodium transport across the medullary
collecting duct [311, I find it attractive to postulate that aldoster-
one directly stimulates the sodium-independent, proton-translo-
cating ATPase at the apical membrane. Direct studies support-
ing this conclusion are not yet available, but the possibility
remains a fertile topic for future research.
Summary
Of particular interest in the patient under discussion today
was an apparently normal antinatriuretic and hydrogen-secre-
tory response to aldosterone, but a virtually absent potassium-
secretory response (see Figs. 1 and 2). Indeed, the fact that
stool potassium also failed to increase in response to intramus-
cular DOCA administration suggests that the defect acquired by
this patient might not have been limited only to the kidney. The
pathogenesis of these findings cannot be adequately explained
by the currently available information that I have reviewed.
Because the urinary potassium excretion did not respond
normally either to mineralocorticoids or to sodium sulfate
infusions, I suspect that the apical membrane and the paracellu-
lar spaces of the cortical collecting duct of this patient were
relatively impermeable to potassium. Unfortunately, this possi-
bility cannot be tested directly.
Questions and answers
DR. ALAN KANTER (Attending Nephrologist, Michael Reese
Hospital): Have similar studies to those performed on your
patient been conducted on individuals with normal renal func-
tion who have been treated with pharmacologic doses of 9-a-
fluorocortisol, for example, patients with the Shy-Drager syn-
drome? Second, how long before the results were obtained was
fludrocortisone discontinued in this patient?
DR. K0KK0: Yes, the renal effects of 9-a-fluorocortisol have
been examined in patients with normal renal function. These
patients respond to a normal replacement dose of 0.05 to I mgi
day by sodium retention and kaliuresis. Unfortunately, there is
flH* + HCO3-
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no easy measure of adequacy of mineralocorticoid replacement.
However, if the patient develops excessive sodium retention
manifested by edema, hypertension, or congestive heart failure,
then the 9-a-fluorocortisol dose is too high. Patients with Shy-
Drager syndrome have autonomic insufficiency and therefore
behave as if they are volume contracted. These patients often
require much higher doses of mineralocorticoids with potassi-
um supplementation to correct hypotension and prevent hypo-
kalemia. Our patient had not received 9-a-fluorocortisol treat-
ment for several days prior to our studies.
DR. JORDAN J. COHEN: How do you explain your patient's
failure to respond to supraphysiologic doses of 9-a-fluorocorti-
sol when she had such a clear-cut response to DOCA, as
evidenced by the positive sodium balance?
DR. KOKK0: That is an exceedingly interesting question. At
the present time I have no satisfactory answer. The only
explanation I can offer is that (1) she did not take her 9-a-
fluorocortisol as prescribed; (2) the oral 9-a-fluorocortisol was
not absorbed; or (3) the 9-a-tIuorocortisol was inactivated by
some unknown mechanism. The patient is quite reliable and I
think she took her medications most of the time. However, it
should be noted that the pH of her urine had dropped from 6.5
to 5.5 prior to the sodium sulfate infusion study. This is relevant
because she received I mg of 9-cr-fluorocortisol the night before
the study. Thus, I am not convinced that she is unresponsive to
oral mineralocorticoids. Indeed, I am unaware of any previous
reports suggesting that a patient responds differently to oral
versus parenteral mineralocorticoids if the doses are compara-
ble. Further examination of this question would require absorp-
tion studies of radiolabeled 9-a-fluorocortisol.
DR. MARSHALL LINDHEIMER (Renal Section, Mitchell Hos-
pital, Chicago): The patient had high renin activity yet respond-
ed to angiotensin II infusions in an exaggerated manner. Were
basal angiotensin II levels measured, and if they too were high,
wasn't the response observed paradoxical?
DR. K0KK0: Although we did not measure basal angiotensin
II values, basal renin values were significantly above normal.
Our results, however, do reveal a normal pressor response to
infused angiotensin. I do not think this response can be consid-
ered "paradoxical," but it is interesting that she was able to
respond to an additional exogenous source of angiotensin.
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital):
Given the patient's severe acidosis, one might have expected
that her urinary calcium excretion would be quite large and that
she would have radiographic abnormalities of her bones. Did
you measure calcium excretion or find radiographic evidence of
osteopenia?
DR. K0KK0: Her serum calcium level has been consistently
low-normal, ranging usually between 8.4 to 8.6 mgldl. We did
not measure urinary calcium excretion, but because I also was
concerned about osteopenia, we measured her bone density and
found it to be low.
DR. COHEN: I think one must be careful about interpreting
values for urinary net acid excretion and drawing conclusions
about the presence or absence of positive hydrogen ion balance
when we don't really have a handle on hydrogen ion production
rate. Although I think it likely that she was in positive hydrogen
ion balance given her high urine pH and relatively low values
for net acid excretion, it is difficult to be certain and doubly
difficult to be quantitative. Wouldn't you agree?
DR. K0KK0: Yes, I agree with you completely. A number of
previous publications have documented that it is difficult to
estimate how much net acid is absorbed from dietary sources
and how much is produced endogenously. For these reasons we
did not even bother to measure the acid ash content of her diet.
It is likely, however, that she is in a steady-state, positive
hydrogen ion balance in view of her serum acid-base parame-
ters documenting metabolic acidosis. Indeed, positive acid
balance may be contributing to the osteopenia.
DR. STEPHEN GLUCK (Renal Section, Mitchell Hospital): I
would like to return to the issue of the acid balance in your
patient. Net acid excretion apparently increased about 10 mEq/
day over a few days and yet the plasma bicarbonate rose from
about 16 to 24 mEq/liter. This rise in bicarbonate seems far
greater than can be explained by the increase in renal acid
excretion. Could this reflect an influence of aldosterone on cell
or bone buffering? Has anyone looked for aldosterone receptors
in bone?
DR. K0KKO: The rise in serum bicarbonate concentration
from 16 to 24 mEq/liter can result from numerous factors.
However, I agree that it is reasonable to postulate that extrare-
nal factors had a role in increasing the serum bicarbonate
concentration. Whereas she was studied on a constant metabol-
ic acid ash diet containing fixed quantities of electrolytes, it is
conceivable that mineralocorticoids might change the fraction
of acid versus alkali absorbed, or it is possible that aldosterone
might influence the participation of bone buffering capacity in
maintenance of acid-base homeostasis. Glucocorticoid recep-
tors have been identified in the bone [73], but to my knowledge
no one has determined whether bone has mineralocorticoid
receptors.
DR. FREDRIC COE (Renal Section, Mitchell Hospital): Your
patient had hypotension that didn't respond to high doses of 9-
a-fluorocortisol. The salt loading produced positive salt balance
but still the blood pressure didn't increase. It only responded
after she got intramuscular DOC or ephedrine. Do you think
that the 1.5 kg body weight gain from intramuscular DOC raised
her blood pressure? When you did the salt loading, more than
140 mEq of sodium was retained, so there would have been at
least a 1 liter increase in extracellular volume. Several days of a
high-salt diet by itself should have given the effect of the DOCA
if volume expansion alone could correct the hypotension.
DR. K0KK0: When the patient gained 1.5 kg of weight, her
diastolic blood pressure increased significantly to the 70 mm Hg
range. I feel that this response is primarily a response to
increased circulatory volume, and not a direct response to
mineralocorticoids. Perhaps the apparent lack of blood pressure
response previously to 9-a-fluorocortisone reflects continued
negative salt balance, either the result of relatively low sodium
intake (lower than the daily urinary output) or the result of her
failure to take the prescribed doses of 9-a-fluorocortisol.
DR. C0E: I also was wondering about the nature of the
membrane disorder. You didn't say what you found in the
colon, which might participate in a putative systemic disorder
of membranes. Was there a potassium secretory or permeability
disorder of the colon? Do you think that she has both an
immunologic disorder affecting the adrenal gland and a general-
ized acquired membrane disorder of permeability, or one or the
other?
DR. KOKK0: The stool potassium excretion did not rise in
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response to DOCA administration. As you know, the stool
normally contains approximately 8% to 10% of the amount of
potassium ingested. Although some differences of opinion exist,
it is generally believed that mineralocorticoids can increase the
fecal potassium excretion rate severalfold. Why our patient did
not increase her fecal potassium excretion must remain conjec-
tural without additional studies.
DR. GARY TOBACK (Renal Section, Mitchell Hospital): Your
presentation suggested that aberrant function at the apical
surface of collecting tubule cells could underlie the abnormali-
ties observed in this patient. What is the evidence to support a
defect at the apical rather than at the basolateral aspect of the
cells?
DR. K0KK0: Because our patient underwent 24-hour balance
studies, it is an overextension of the existing data to conclude
that the failure to excrete normal amounts of potassium was
localized to the cortical collecting tubule. To suggest that the
failure of kaliuresis in response to mineralocorticoids is the
result of decreased apical permeability of the collecting duct is
pure speculation. However, this speculation is based on exist-
ing physiologic data. A decrease in potassium secretion could
result from a number of factors, but since you ask about
preferential localization of the secretory defect to the apical
rather than the basolateral membrane I therefore will limit my
remarks to those two possibilities. In principle, a decrease in
potassium secretion could result from either an increase in
basolateral potassium permeability or a decrease in apical
permeability. An increase in basolateral potassium permeability
would increase efflux of potassium from the cell to the blood
side. Here it would be recycled into the cell by the sodium-
potassium ATPase pump. This transport would set up a futile
cycle. On the other hand, a decrease in apical cell membrane
permeability would also decrease potassium secretion but
would not increase recycling of potassium across the basolater-
al membrane. Clearly, either of these two mechanisms could be
operative. Normally, permeable apical membrane responds to
sodium sulfate infusion by increasing potassium secretion down
a more favorable electrochemical gradient. We did not demon-
strate this in our studies. Thus, our studies indirectly suggest
that the apical membrane of our patient's collecting duct was
less permeable to potassium than would be expected under
normal conditions.
DR. COHEN: You hypothesized that this patient's adrenal
problem might have been autoimmune in nature because she
had an associated B12 deficiency. Is it possible that her renal
tubular problem is yet another manifestation of autoimmunity?
We know that patients with lupus can develp hyperkalemia
because of a defect in renal potassium secretion. As I recall,
many but not all such patients have immunoglobulin deposition
around their renal tubules, as revealed by immunofluorescence
microscopy. Can it be argued that this patient has a lupus-like
defect?
DR. K0KK0: Hyperkalemia, acidosis, and a tendency to-
wards salt wastage comprise a constellation of findings common
to a number of disease processes. Lupus is an example. Other
examples include various immune-mediated processes. It is
interesting that she is allergic to many foods including cheeses
and various types of drugs. For that reason I suspected that she
had interstitial nephritis in response to some allergen. Howev-
er, she had no monocytic or eosinophilic cuffing of either the
distal or collecting duct segments. Indeed, these segments
appeared entirely normal both in the cortex and medulla. Also,
immunofluorescence studies failed to show any deposits or
abnormalities. The serum studies for collagen-vascular diseases
also were negative. Therefore I doubt that her disease process
is related to lupus.
DR. ARNOLD BERNS (Attending Nephrologist, Michael Reese
Hospital): Your patient sustained numerous episodes of rather
severe hyperkalemia; however, you did not describe serious or
life-threatening cardiac effects. Does your hypothesis include
an explanation for her apparent cardiac tolerance of severe
hyperkalemia?
DR. KOKKO: You are correct, of course, in pointing out that
hyperkalemia is associated with asystole. Indeed, it is rare to
see patients survive who have potassium concentrations as high
as 10 mEq/liter. In our patient, we have no documentation of
cardiac arrhythmias unless her syncopal episodes were related
to arrhythmia. In many patients with persistent hyperkalemia,
potassium adaptation occurs and the heart becomes protected
from the toxic effects of hyperkalemia. The details of cardiac
adaptation to hyperkalemia are poorly understood. In potassi-
um adaptation there is an increased renal and gastrointestinal
excretion of potassium for any given exogenous load, but this is
not the mechanism by which the heart is protected.
DR. KAI LAU (Renal Division, Michael Reese Hospital): One
of the causes for resistance to the kaliuretic effect of DOCA is
potassium depletion. On the face of it, this woman seems, if
anything, to have had a potassium surfeit. However, she was
receiving a very low potassium diet for several days and this
raises the possibility that she might have been potassium
depleted. Do you have muscle biopsy data or other evidence to
exclude this possibility?
DR. KOKKO: No, I did not perform a muscle biopsy. Indeed,
the serum potassium concentration does not necessarily reflect
total body potassium stores, but I doubt that she was potasium
deficient given her persistently low urinary potassium excretion
and frank hyperkalemia of years duration.
DR. DANIEL BATLLE (Renal Division, University of Illinois,
Chicago): In the patient under discussion, selective deficiency
of aldosterone, one of the most common causes of hyperkale-
mia, was carefully documented. What is unusual is the severity
of the hyperkalemia despite the fact that renal function was only
moderately impaired. Do you think that impaired extrarenal
potassium disposal could have contributed to the hyperkalemia
in this patient? The acidosis could be easily explained by the
inhibiting effects of hyperkalemia and aldosterone deficiency on
ammonium excretion. That acidosis improved when plasma
potassium was lowered by DOCA administration supports this
possibility. What is very interesting, in my view, is the urine
pH, which was above 5.5 at a time when she was acidotic. That
requires explanation because, as you noted, patients with
aldosterone deficiency are consistently able to lower the urine
pH well below 5.5 even when they are only slightly acidotic.
Hence, your patient may have a tubular defect for hydrogen ion
secretion in addition to having aldosterone deficiency, a pattern
that we described in some patients with obstructive uropathy
and sickle-cell disease [74, 75]. Perhaps additional studies of
urinary acidification might have disclosed such a defect. For
instance, a defect in hydrogen ion secretion often can be
detected by a failure of the urine PCO2 to increase normally
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after bicarbonate loading; this test is a very sensitive marker of
distal acidification. It would also be of interest to know the
response of urinary pH and acid excretion to sodium sulfate
infusion. The combined analysis of the kaliuretic and acidifica-
tion response to sodium sulfate in patients receiving mineralo-
corticoids allows one to distinguish between pure selective
aldosterone deficiency and voltage-dependent distal renal tubu-
lar acidosis [76]. Inability to lower urine pH below 5.5 and
failure to increase potassiun excretion normally in response to
this maneuver would suggest the presence of a defect for
hydrogen ion and potassiuln secretion likely secondary to
impaired distal sodium transport (that is, the presence of a
voltage-dependent defect). Again, the patient under discussion
is "unique" in that she was able to lower urine pH when large
doses of DOCA were given. It should be noted, however, that a
fall in urine pH below 5.5 was not observed until the third daily
dose of DOCA, whereas in our patients only a single dose of
mineralocorticoid was given [74]. Nevertheless, the ability of
your patient to lower urine pH with DOCA suggests that
collecting duct hydrogen ion secretion can be normalized in
certain patients in whom large doses of mineralocorticoid are
required because of an intrinsic defect in collecting duct hydro-
gen ion secretion or a "dormant" transport mechanism owing
to prolonged aldosterone deficiency.
DR. K0KK0: I will first deal with your questions concerning
extrarenal potassium disposal. It is well appreciated that the
hyperkalemia of adrenal insufficiency cannot be the result only
of decreased urinary excretion of potassium. Thus it would not
be surprising at all if part of her hyperkalemia were due to an
abnormal transcellular distribution of potassium. Studies have
shown that epinephrine, norepinephrine, and aldosterone have
roles in regulating the normal extrarenal mechanism of potassi-
um transport. It should be pointed out that plasma epinephrine
values were normal. Whether the elevated norepinephrine
values had any role in her persistent hyperkalemia is not clear.
Recent studies have shown that stimulation of alpha-adrenergic
receptors in healthy human volunteers impairs extrarenal up-
take of potassium [77]. We also know that in animals, aldoster-
one is necessary for normal extrarenal potassium disposal [78].
Thus, it is possible that part of this patient's hyperkalemia is the
result of deficient extrarenal mechanisms of potassium
homeostasis,
Now to your second question. We did not examine this
patient's hydrogen secretory capacity in the detail that you
suggested. Specifically, we did not measure her urinary PCO2.
We did measure the urinary pH in response to sodium sulfate
infusion. However, our studies were designed mainly to exam-
ine potassium secretion and therefore we added bicarbonate to
our sodium sulfate infusion. Thus, the urinary pH is locked in
an alkaline direction and although we lost the aspect of the test
that measures hydrogen secretion, we did gain a measure of
potassium secretion. She clearly was unable to increase potassi-
um secretion to normal levels in spite of administration of 9-a-
fluorocortisol the night before the test and 10 mg of DOCA
intramuscularly on the morning of the test.
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